Acute myeloid leukemia (AML) with t(6;9)(p23;q34) is well known to have a poor prognosis treated with chemotherapy and autotransplantation. The presence of this karyotype is an indicator for allogeneic hematopoietic stem cell transplantation (HSCT); however, the impact of t(6;9)(p23;q34) on the HSCT outcome remains unclear. We conducted a matchedpair analysis of de novo AML patients with and without t(6;9)(p23;q34) using data obtained from the Japanese HSCT data registry. A total of 57 patients with t(6;9)(p23;q34) received transplants between 1996 and 2007, and 171 of 2056 normal karyotype patients matched for age, disease status at HSCT and graft source were selected. The overall survival, disease-free survival, cumulative incidence of relapse and the non-relapse mortality in t(6;9)(p23;q34) patients were comparable to those for normal karyotype patients. A univariate analysis showed that t(6;9)(p23;q34) had no significant impact on the overall survival. These findings suggest that allogeneic HSCT may overcome the unfavorable impact of t(6;9)(p23;q34) as an independent prognostic factor.
Introduction
Acute myeloid leukemia (AML) is a hematological malignancy resulting from the proliferation of leukemic stem cells. Because of the resistance of leukemic stem cells to chemotherapy, 1 longterm survival is generally seen in only 50% of patients treated with chemotherapy alone. Therefore, allogeneic stem cell transplantation (HSCT) is often considered as a curative treatment option. 2 AML is the most common indication for HSCT in North America and in Japan, but fatal transplant-related adverse events are difficult to avoid, despite the improvements in supportive treatment in recent years. Therefore, treatment of AML is hard to standardize, and the attending physician must make a decision on a case-by-case basis, weighing the advantages and disadvantages of HSCT.
The results of previous large clinical trials have indicated that abnormalities of the chromosomal karyotype are considered to be one of the most powerful factors to predict the patient prognosis.
3,4 AML with the unfavorable cytogenetic risk group, such as a partial deletion of the long arm of chromosome 7 (del (7q)), monosomy of chromosome 7 (À7) or with a complex karyotype is considered to be a good indication for HSCT, even during the first remission, because of the high cytogenetic risk associated with chemotherapy and the beneficial outcome that can be achieved by HSCT. [5] [6] [7] [8] The translocation of chromosome (6;9)(p23;q34) forming the DEK/NUP214 fusion mRNA is observed in B1% of AML cases. 9 The characteristics of AML with t(6;9)(p23;q34) are known to include development at a younger age, 10 resistance to chemotherapy and a very poor prognosis. 9 Therefore, the presence of this karyotype in AML patients is an indication for HSCT; however, the impact of t(6;9)(p23;q34) on the outcome of HSCT remains unclear because of the rarity of this entity. We conducted a retrospective study to examine the outcomes of HSCT in AML patients with t(6;9)(p23;q34) using the data from the Japan Society for Hematopoietic Cell Transplantation Data Registry.
Materials and methods

Study population
Clinical data were collected from the databases of the Japan Society for Hematopoietic Cell Transplantation and the Japan Cord Blood Bank Network using a standardized report form. Follow-up reports were submitted at 100 days, 1 year and annually after HSCT. Patients with de novo AML aged 15 years or older at the time of first HSCT and who received the transplant between January 1996 and December 2007 were extracted from the databases. We compared the clinical features and the outcomes among the patients with t(6;9)(p23;q34) and the patients with a normal karyotype in G-band staining. Cytogenetic data were analyzed according to the Southwestern Oncology Group criteria in each institution 7 instead of by central review. We selected patient pairs with t(6;9)(p23;q34) and the normal karyotype using an optimal matching method with the following three matching factors: recipient age, disease status at HSCT and graft source. This study was approved by the Committee for Nationwide Survey Data Management of the Japan Society for Hematopoietic Cell Transplantation. Written informed consent was obtained in accordance with the Declaration of Helsinki.
Statistical analysis
The overall survival (OS) was defined as the number of days from HSCT until death from any cause. Disease relapse was defined as the number of days from HSCT to relapse of the underlying disease. Non-relapse mortality was defined as death without relapse. Any patient who was alive at the last-follow-up date was censored. All statistical analyses were performed using the R version 2.13.0 software program (R Foundation for Statistical Computing; http://www.r-project.org). Probabilities and times-to-events were compared between the two groups using the Mantel-Haenszel method and stratified Cox's proportional hazard modeling, respectively. The cumulative incidences of non-relapse mortality and relapse were calculated considering each other event as a competing risk, and were compared using the stratified Grey test.
11 P values were two sided, and outcomes were considered to be significant when Pp0.05.
Results
Patients' characteristics
A total of 2577 AML cases met the inclusion criteria. The number of cases with t(6;9)(p23;q34) and a normal karyotype was 57 and 2056, respectively; and 171 patients with the normal karyotype were selected for matched-pair analysis by a 1:3 matching ratio. The characteristics of the patients are shown in Table 1 ; there were no statistically significant differences between the t(6;9)(p23;q34) patients and the normal karyotype patients except the use of total body irradiation as a preconditioning regimen.
Survival, relapse and non-relapse mortality
The probability of OS in the patients with t(6;9)(p23;q34) was as good as that for patients with a normal karyotype (the probability of 5-year OS in t(6;9)(p23;q34) and normal karyotype patients was 45 and 40%, respectively; Figure 1a ). When the t(6;9)(p23;q34) patients and the normal karyotype patients were further categorized according to the disease status at HSCT, the OS of the t(6;9)(p23;q34) patients and the normal karyotype patients were comparable in both the complete remission (CR) at HSCT patients and the non-CR at HSCT patients (Figure 1b) . The probability of disease-free survival in these patients was also not significantly different (the probability of 5-year disease-free survival in patients with t(6;9)(p23;q34) and the normal karyotype was 42 and 33%, respectively; Figure 1c ). The cumulative incidence of relapse (Figure 2a ) and the non-relapse mortality (Figure 2b ) in t(6;9)(p23;q34) patients were also comparable to those for normal karyotype patients (the 5-year cumulative incidence was 42% in t(6;9)(p23;q34) patients and 45% in normal karyotype patients for relapse (P ¼ 0.34) and 16 and 22% (P ¼ 0.85) for non-relapse mortality). The prognostic factors affecting OS revealed that there were no significant differences related to karyotype, gender, gender mismatch between donor and recipient, human leukocyte antigen disparity, recipient cytomegalovirus serostatus and use of total body irradiation for the preconditioning regimen by the univariate analyses (Table 2) .
Discussion
Previous reports have confirmed the negative impact of t(6;9)(p23;q34) on the outcome after standard-dose chemotherapy and high-dose therapy with autologous stem cell transplantation in patients with AML. 9, 10 The current matchedpair analysis of the nationwide survey demonstrated that the OS and the non-relapse mortality, as well as the relapse rate, were independent of the presence of t(6;9)(p23;q34) in allogeneic HSCT recipients, thus suggesting that allogeneic HSCT may be able to overcome the unfavorable effect of t(6;9)(p23;q34) in AML patients.
However, it is difficult to draw any firm conclusions regarding the results of the present analysis owing to the small number of patients in the matched-pairs subsets. These findings require confirmation in larger studies specifically in examining the impact of t(6;9)(p23;q34) status. Nevertheless, the suggestion that allogeneic HSCT appears to overcome the adverse survival impact of t(6;9)(p23;q34) is supported by other studies. 12, 13 In a EBMT study of AML patients with t(6;9)(p23;q34), allogeneic HSCT produced responses that were independent of t(6;9)(p23;q34), and the 3-year OS of patients with t(6;9)(p23;q34) was as high as 51±7%, comparable to AML patients with the normal karyotype. 13 Also, the incidence of relapse following allogeneic HSCT appeared to be similar in patients with t(6;9)(p23;q34) compared with those without Abbreviations: CR, complete remission; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; TBI, total body irradiation.
HSCT improves the prognosis of t(6;9)(p23;q34) AML K Ishiyama et al Abbreviations: CMV, cytomegalovirus; HLA, human leukocyte antigen; TBI, total body irradiation.
HSCT improves the prognosis of t(6;9)(p23;q34) AML K Ishiyama et al t(6;9)(p23;q34). However, the EBMT study made it somewhat difficult to determine whether HSCT would lead to a good outcome, because 87% of the patients were transplanted while in CR, whereas only 29 of 57 (51%) patients in our study received HSCT in CR, which is a more clinically relevant expectation, as a CR is difficult to achieve in these patients.
In conclusion, the current study showed that AML patients with t(6;9)(p23;q34) can be expected to have a post-transplant survival comparable to patients with a normal karyotype, thereby supporting the opinion that they are good candidates for HSCT.
